Press release
Fuchs Endothelial Corneal Dystrophy Market Shows Strong Growth Potential with Emerging Therapeutics by 2036 - DelveInsight | Kowa Pharmaceuticals, Trefoil Therapeutics, Santen
The Key Fuchs Endothelial Corneal Dystrophy Companies in the market include - Kowa Pharmaceuticals, Trefoil Therapeutics, Santen, ActualEyes, Alcon, Emmecell, AJL Ophthalmic SA, Massachusetts Eye and Ear, KeraMed, Inc, Presbia Plc., and others.
Get a Free sample for the Fuchs Endothelial Corneal Dystrophy Market Report [https://www.delveinsight.com/report-store/fuchs-endothelial-corneal-dystrophy-fecd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=mpr]
Some of the key facts of the Fuchs Endothelial Corneal Dystrophy Market Report:
The Fuchs Endothelial Corneal Dystrophy market size was valued at around USD 858 million in 2023 and is anticipated to witness significant growth during the forecast period from 2026 to 2036.
In 2025, the total diagnosed prevalent cases of FECD in the 7MM were approximately 19.3 million. These cases are projected to increase further during the study period (2022-2036).
Among the 7MM, the US accounted for the largest market size of Fuchs Endothelial Corneal Dystrophy with approximately USD 394 million in 2023.
In 2025, the United States accounted for the highest proportion of diagnosed prevalent cases of FECD with approximately 6.6 million cases throughout the 7MM. This was followed by Japan, with about 3.2 million cases, while Spain accounted for the lowest cases at approximately 1.4 million.
Among EU4 and the UK, Germany accounted for the largest market of Fuchs Endothelial Corneal Dystrophy with nearly USD 88 million in 2023, followed by Italy with nearly USD 67 million, while Spain accounted for the least with around USD 50 million.
There is a higher prevalence among females across the 7MM. In the US in 2025, approximately 6 million cases among males and 10.8 million cases among females were accounted, indicating a female predominance.
FECD is a progressive hereditary disease affecting the cornea's endothelial layer, characterized by corneal edema, guttae formation, reduced visual acuity, and can potentially lead to corneal blindness.
The total market size of the Fuchs Endothelial Corneal Dystrophy treatment market is anticipated to experience growth during the forecast period due to the emergence of new and effective treatments, namely, Ripasudil/K-321, TTHX1114/NM141, STN1010904/AE-001, and others.
Key Fuchs Endothelial Corneal Dystrophy Companies: Kowa Pharmaceuticals, Trefoil Therapeutics, Santen, ActualEyes, Alcon, Emmecell, AJL Ophthalmic SA, Massachusetts Eye and Ear, KeraMed, Inc, Presbia Plc., and others
Key Fuchs Endothelial Corneal Dystrophy Therapies: Ripasudil (K-321), TTHX1114 (NM141), STN1010904/AE-001 (sirolimus), and others
The Fuchs Endothelial Corneal Dystrophy epidemiology based on gender analyzed that FECD occurs in both men and women, with a higher prevalence among females across the 7MM.
The Fuchs Endothelial Corneal Dystrophy market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage FECD pipeline products will significantly revolutionize the FECD market dynamics.
Fuchs Endothelial Corneal Dystrophy Overview
Fuchs Endothelial Corneal Dystrophy (FECD) is a progressive hereditary disease affecting the cornea's endothelial layer. It is characterized by corneal edema, guttae formation, reduced visual acuity, and can lead to corneal blindness. FECD is more common in women, and its prevalence varies geographically in the 7MM. FECD is associated with genetic factors, with mutations in genes like COL8A2, SLC4A11, TCF4, and ZEB1 implicated in its development.
To Know in detail about the Fuchs Endothelial Corneal Dystrophy market outlook, drug uptake, treatment scenario and epidemiology trends, Fuchs Endothelial Corneal Dystrophy Market Forecast: https://www.delveinsight.com/report-store/fuchs-endothelial-corneal-dystrophy-fecd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=mpr
Fuchs Endothelial Corneal Dystrophy Epidemiology
The Fuchs Endothelial Corneal Dystrophy epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Fuchs Endothelial Corneal Dystrophy Epidemiology Segmentation:
The Fuchs Endothelial Corneal Dystrophy market report proffers epidemiological analysis for the study period 2022-2036 in the 7MM segmented into:
*
Total Diagnosed Prevalent Cases of Fuchs Endothelial Corneal Dystrophy (FECD) in the 7MM
*
Gender-specific Cases of Fuchs Endothelial Corneal Dystrophy (FECD) in the 7MM
*
Age-specific Cases of Fuchs Endothelial Corneal Dystrophy (FECD) in the 7MM
*
Grade-specific Cases of Fuchs Endothelial Corneal Dystrophy (FECD) in the 7MM
Download the report to understand which factors are driving Fuchs Endothelial Corneal Dystrophy epidemiology trends @ Fuchs Endothelial Corneal Dystrophy Epidemiology Forecast [https://www.delveinsight.com/report-store/fuchs-endothelial-corneal-dystrophy-fecd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=mpr]
Fuchs Endothelial Corneal Dystrophy Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Fuchs Endothelial Corneal Dystrophy market or expected to get launched during the study period. The analysis covers FECD market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Fuchs Endothelial Corneal Dystrophy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Fuchs Endothelial Corneal Dystrophy Therapies and Key Companies
Ripasudil (K-321): Kowa Pharmaceuticals - A rho-kinase inhibitor currently in Phase III of clinical development for the treatment of FECD.
TTHX1114 (NM141): Trefoil Therapeutics - An engineered fibroblast growth factor-1 variant designed to protect corneal endothelial cells from stress and injury. Trefoil announced positive Phase II (STORM) trial results showing corneal regeneration and vision recovery.
STN1010904/AE-001 (sirolimus): Santen/ActualEyes - An mTOR inhibitor eye drop that suppresses the formulation of guttae and apoptosis of endothelial cells. Currently being evaluated in Phase IIa of clinical trials.
Discover more about therapies set to grab major FECD market share @ https://www.delveinsight.com/report-store/fuchs-endothelial-corneal-dystrophy-fecd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=mpr
Fuchs Endothelial Corneal Dystrophy Market Drivers
Increasing Disease Prevalence and Patient Awareness: Rising awareness about Fuchs Endothelial Corneal Dystrophy may increase market size in the coming years, resulting in an increase in the prevalence of FECD patients seeking diagnosis and treatment.
Advancement in Diagnostic Techniques: Development of improved diagnostic tools such as deep learning algorithms, Scheimpflug tomography, and anterior segment optical coherence tomography (AS-OCT) are enhancing early detection capabilities and disease monitoring.
Emergence of Innovative Therapeutics: The development of novel treatment approaches including rho-kinase inhibitors and engineered growth factors represents a significant shift from symptomatic management to disease-modifying therapies.
Growing Unmet Medical Needs: Current treatment options provide only temporary symptomatic relief without addressing the underlying cause of endothelial layer dysfunction, creating substantial opportunities for disease-modifying therapies.
Fuchs Endothelial Corneal Dystrophy Market Barriers
Limited Approved Treatment Options: The market currently lacks disease-modifying therapies approved specifically for FECD, with treatment options limited primarily to symptomatic management with topical sodium chloride and steroids.
High Cost of Novel Therapies: The high cost of emerging therapies for the treatment is a major factor restraining the growth of the market, increasing the economic burden on patients and limiting accessibility.
Diagnostic Challenges: Although various diagnostic tools have been developed, there is still a need to improve the availability and accessibility of image analysis tools for early detection, monitoring of disease progression, and customized therapeutic interventions.
Complex Disease Mechanism: FECD is influenced by genetic factors and multiple pathophysiological mechanisms, making treatment development and drug efficacy demonstration challenging.
Patient Accessibility Issues: Geographic variations in disease prevalence and disparities in access to advanced diagnostic and therapeutic options remain significant barriers to market expansion.
Scope of the Fuchs Endothelial Corneal Dystrophy Market Report
Study Period: 2022-2036
Coverage: 7MM [The United States, EU4 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Fuchs Endothelial Corneal Dystrophy Companies: Kowa Pharmaceuticals, Trefoil Therapeutics, Santen, ActualEyes, Alcon, Emmecell, AJL Ophthalmic SA, Massachusetts Eye and Ear, KeraMed, Inc, Presbia Plc., and others
Key Fuchs Endothelial Corneal Dystrophy Therapies: Ripasudil (K-321), TTHX1114 (NM141), STN1010904/AE-001 (sirolimus), and others
Fuchs Endothelial Corneal Dystrophy Therapeutic Assessment: FECD current marketed and FECD emerging therapies
Fuchs Endothelial Corneal Dystrophy Market Dynamics: FECD market drivers and FECD market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Fuchs Endothelial Corneal Dystrophy Unmet Needs, KOL's views, Analyst's views, FECD Market Access and Reimbursement
To know more about Fuchs Endothelial Corneal Dystrophy companies working in the treatment market, visit @ Fuchs Endothelial Corneal Dystrophy Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/report-store/fuchs-endothelial-corneal-dystrophy-fecd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=mpr]
Table of Content
1 Key Insights
2 Report Introduction
3 FECD Market Overview at a Glance
4 Methodology of FECD Epidemiology and Market
5 Executive Summary of FECD
6 Key Events
7 Disease Background and Overview
8 Epidemiology and Patient Population
9 Patient Journey
10 Emerging Drugs
11 FECD: Market Analysis
12 KOL Views
13 SWOT Analysis
14 Unmet Needs
15 Market Access
16 Appendix
17 DelveInsight Capabilities
18 Disclaimer
19 About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Mehul Malhotra
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com
Media Contact
Company Name: DelveInsight
Contact Person: Mehul Malhotra
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=fuchs-endothelial-corneal-dystrophy-market-shows-strong-growth-potential-with-emerging-therapeutics-by-2036-delveinsight-kowa-pharmaceuticals-trefoil-therapeutics-santen]
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Fuchs Endothelial Corneal Dystrophy Market Shows Strong Growth Potential with Emerging Therapeutics by 2036 - DelveInsight | Kowa Pharmaceuticals, Trefoil Therapeutics, Santen here
News-ID: 4539059 • Views: …
More Releases from ABNewswire
Cytokine Release Syndrome Market Emerging as a High-Growth Healthcare Investment …
The Key Cytokine Release Syndrome Companies in the market include - Genentech, Swedish Orphan Biovitrum (sobi), Incyte, Kite, A Gilead Company, Jazz Pharmaceuticals, Fred Hutchinson Cancer Center, Ontario Clinical Oncology Group, GlaxoSmithKline, UNC Lineberger Comprehensive Cancer Center, SCRI Development Innovations and others.
The Cytokine Release Syndrome market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cytokine Release Syndrome pipeline…
Dry Age-Related Macular Degeneration Market is Projected to Grow at ~19.2% CAGR …
Key companies like Astellas Pharma/Iveric Bio, Apellis Pharmaceuticals, Belite Bio, Alkeus Pharmaceuticals, Aviceda Therapeutics, Allegro Ophthalmics, Johnson & Johnson Innovative Medicine, and others are leading the exponential growth in the market.
DelveInsight's "Dry Age-Related Macular Degeneration Market Insight, Epidemiology and Market Forecast - 2036" report delivers an in-depth understanding of Dry Age-Related Macular Degeneration (AMD), historical and forecasted epidemiology as well as the Dry AMD market trends in the United States,…
CAR-T Pipeline Expands as 180+ Companies Driving Innovation in the Therapeutics …
DelveInsight's "CAR T-Cell Therapy Pipeline Insight 2026" report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in the CAR T-Cell Therapy pipeline landscape. It covers the CAR T-Cell Therapy Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the CAR T-Cell Therapy Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious…
Atopic Dermatitis Pipeline Shows Potential with Active Contributions from 100+ K …
DelveInsight's "Atopic Dermatitis Pipeline Insight 2026" report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in the Atopic Dermatitis pipeline landscape. It covers the Atopic Dermatitis Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Atopic Dermatitis Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates…
More Releases for Fuchs
Lubricants Market SWOT Analysis by Leading Expert: Castrol, Fuchs, Lukoil
The "Lubricants Market" intelligence report, just published by USD Analytics Market, covers a micro-level study of important market niches, product offers, and sales channels. To determine market size, potential, growth trends, and competitive environment, the Lubricants Market provides dynamic views. Both primary and secondary sources of data were used to generate the research, which has both qualitative and quantitative depth. Several of the major figures the study featured Shell, ExxonMobil,…
Global Photoelectric Sensors Market 2019 - Pepperl+Fuchs, SICK, Balluff, Eaton
A photoelectric sensor is a special type of proximity sensor used to detect the distance, absence, and presence of any object in its predefined perimeter.
Scope of the Report:
This report focuses on the Photoelectric Sensors in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The rising awareness for maintaining the safety of industrial…
Global Encoder Market 2017 - Tamagawa, Heidenhain, Nemicon, Baumer, Pepperl-fuch …
The Report describe Encoder Introduction, product scope, market overview, opportunities, risk, driving force also to analyze the top manufacturers, with sales, revenue, and price, market type and application, with sales market share and growth rate by type, application, from 2017 to 2022
The research study Global Encoder Industry offers strategic assessment of the Global Encoder market. The industry report focuses on the growth opportunities, which will help the Global Encoder industry…
Inclination Sensors Market 2017- Pepperl & Fuchs, SICK, Baumer
Marketreports.biz, recently published a detailed market research study focused on the "Inclination Sensors Market" across the global, regional and country level. The report provides 360° analysis of "Inclination Sensors Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Inclination Sensors industry, and estimates the future trend of Inclination Sensors market on…
Inductive Sensor Market 2017- Pepperl+Fuchs, Sick, Omron
Marketreports.biz, recently published a detailed market research study focused on the "Inductive Sensor Market" across the global, regional and country level. The report provides 360° analysis of "Inductive Sensor Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Inductive Sensor industry, and estimates the future trend of Inductive Sensor market on…
Arabia Lubricant Market 2017 - Mobil, Castrol, Alhamrani-Fuchs Petroleum Saudi A …
The Global Arabia Lubricant Market 2017 Industry Research Report focused on global and regional market, major manufacturers, as well as the current state of the Arabia Lubricant industry. First, "Global Arabia Lubricant Industry 2017" report analyzed the basic scope of this industry like definition, specification, classification, application, industry policy, news analysis and Arabia Lubricant industry chain structure.
Major Companies Covered in this report:-
Mobil
Castrol
Alhamrani-Fuchs Petroleum Saudi Arabia
Petromin
Shell
ExxonMobil
BP
TOTAL
Chevron
Sinopec
FUCHS
Valvoline
Idemitsu Kosan
LUKOIL
JX Group
K Lubricants
ConocoPhillips
Hyundai Oilbank
Request For…
